Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novagold Resources Inc. (NG) vs Zoetis Inc (ZTS) Price & Performance

Novagold Resources Inc.Trade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Novagold Resources Inc. vs Zoetis Inc — how do they compare? Novagold Resources Inc. trades at $6.37 (market cap $2.73B), while Zoetis Inc trades at $75.72 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 11.4× Novagold Resources Inc.'s market cap, and Zoetis Inc pays a 2.82% dividend while Novagold Resources Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novagold Resources Inc. for 0 Days and Zoetis Inc for 71 Days on average.

NGZTS
Market Cap
$2.73B$31.11B
Volume
6,599,1882,515,954
Sector
Basic MaterialsHealth
52-Week High
$14.20$147.53
52-Week Low
$5.18$69.09
Typical Hold Time
0 Days71 Days
Enterprise Value
$2.57B$38.68B
Dividend Yield
—2.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novagold Resources Inc.

NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.

The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.

Zoetis Inc

Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.

ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NG
100% Buy0% Sell
Avg holding period · 0 Days
ZTS
0% Buy100% Sell
Avg holding period · 71 Days

About Novagold Resources Inc.

NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.

Read more on NG →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →